Precision Virologics and Bharat Biotech Jointly Obtain Rights to Intranasal COVID-19 Vaccine Technology

Precision Virologics | September 23, 2020

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine candidate having shown unprecedented levels of protection in mouse studies. This technology and data recently was published in Cell and Nature. "The ability to accomplish effective immunization with a single nasal dose is a major advantage, offering broader reach and easier administration," said Precision Virologics Interim CEO David T. Curiel, MD, PhD. "An effective nasal dose not only protects against COVID-19, but it also prevents the spread of the disease by directly targeting the cells that line the nose and throat. Most other vaccine candidates currently under development can't do that." Based on these exceptional findings, the National Institutes of Health is advancing studies in non-human primates. Phase I trials – a single nasal dose – will take place at Saint Louis University's Vaccine and Treatment Evaluation Unit. Bharat Biotech, upon obtaining regulatory approvals, will pursue clinical trials in India and undertake large-scale manufacture of the vaccine at its GMP facility in Genome Valley, India.

Spotlight

Laboratory where we determine the proteins in food.

Spotlight

Laboratory where we determine the proteins in food.

Related News

Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

Vedere Bio | October 29, 2020

Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and will be eligible for up to $130 million in milestone payments, for a total of $280 million. Based on technology from the laboratories of Drs. Ehud Isacoff and John G. Flannery of UC Berkeley, and technology directed at enhanced ocular gene therapy delivery arising jointly between UC Berkeley and the School of Veterinary Medicine at the University of Pennsylvania, Vedere Bio was formed in the Atlas Venture incubator in June 2019. The company was launched with a $21 million Series A financing and began lab operations at LabCentral in Cambridge, MA where it advanced its lead programs from concept to development candidate within one year. Immediately prior to the acquisition, certain earlier-stage vision restoration and vision preservation assets leveraging the company's ocular gene therapy toolbox were spun out into a newly formed entity – Vedere Bio II, Inc.

Read More

MEDTECH

CosmosID Launches Accurate and Easy Functional Microbiome Analysis with New Software Platform, CosmosID-HUB: Microbiome

CosmosID | September 27, 2021

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming and challenging. CosmosID®, known for the most accurate, multi-kingdom, strain level taxonomic profiling technology, has added a functional analysis module to its popular online user-interface, renamed 'CosmosID-HUB: Microbiome'. Now, in addition to microbiome sequencing services out of its Germantown, MD, laboratory, its industry-leading team of bioinformaticians and software developers, has unveiled a suite of new features for seamless analysis of the genomic potential of microbial communities: Direct links from the platform to MetaCyc and GO terms databases. Data import via direct upload, Illumina BaseSpace & automated SRA import from NCBI with analysis speeds up to 19X faster than open-source tools. Find your organism or gene/pathway of interest with search functions, exportable charts & visualizations. Comparative analysis software, complete with dynamic charts, graphs, and statistical significance testing. Easy-to-navigate user interface OR command-line access. Applicable to almost any sample type Applicable to both metagenomic and metatranscriptomics data Knowing the combined genomic potential of a microbial community is proving indispensable for practical applications of translational microbiome science, This cutting edge, accurate, easy and fast functional analysis feature is part of our ongoing mission to provide everything researchers need to complete their end-to-end microbiome analysis and lower the barrier to entry for those interested in the field. - CosmosID CEO, Manoj Dadlani. The updated web application is part of CosmosID's microbial genomics platform, CosmosID-HUB, which is continually expanding with various apps and modules for analyzing microbial communities and for inferring translational and actionable microbiome insights. Currently, CosmosID-HUB: Microbiome provides options for discovering antimicrobial resistance and virulence markers, microbial taxa (composition) and function whereas CosmosID-HUB: COVID-19 is a separate module for detecting the presence of COVID-19 and characterizing variants of concern/interest in both clinical and wastewater specimens. Researchers have the flexibility to access and pay for the type of analysis they require. Soon, CosmosID-HUB will include a revolutionary web application for microbiome multi-dimensional feature testing and multi-omics analysis. In addition to strain-level resolution enabled by its curated databases of over 170,000 genomes and gene sequences, CosmosID® also offers next-generation sequencing services. To date, the company has demonstrated its best-in-class technology and won three different challenges for its detection accuracy, including both PrecisionFDA challenges as well as the Janssen/DNAnexus Mosaic 'Strain' challenge. About CosmosID® CosmosID® provides end-to-end solutions unlocking the microbiome. A provider of CLIA-certified & ICH-GCP compliant NGS Services and Bioinformatics Solutions, CosmosID offers a range of validated and optimized workflows for a range of applications including pharmaceutical R&D, infectious disease diagnostics, environmental testing, microbiome research, animal health, cosmetics & personal care as well as many more. CosmosID also offers independently validated, industry-leading pipelines for processing metagenomic data, yielding multi-kingdom, strain-level resolution with leading sensitivity and precision as well as functional characterization

Read More

RESEARCH

Vipergen Collaborates with Anavo Therapeutics to Support Phosphatase-Targeted Discovery Programs

Vipergen ApS, Anavo Therapeutics | May 18, 2021

Vipergen, a leading supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technologies, has signed a drug discovery service agreement with Anavo Therapeutics. Vipergen will use its patented high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets, according to the terms of the agreement. The agreement's financial terms were not disclosed. "Vipergen's novel solutions to DNA-encoded libraries are useful components for ramping up our patented drug development activities against a chosen portfolio of innovative goals," said Anavo CEO Birgit Zech, Ph.D. "We are excited to collaborate with Vipergen to kick-start Anavo's proprietary drug development activities as we strive to create a comprehensive and secure platform for phosphatase drug discovery against all valuable targets in the space." "We are delighted to have been chosen by Anavo, a new company focusing on understanding the full therapeutic potential of human phosphatase biology in the development of new cancer therapies," said Nils Hansen, Ph.D., Chief Executive Officer of Vipergen. "Phosphatases are a rich target space that has been thought to be impenetrable for decades. We are excited to use our DNA-encoded library technology to quickly produce high-quality hits and leads as part of Anavo's comprehensive approach to finding and improving small-molecule phosphatase activity modulators." About Vipergen ApS Vipergen is the world's largest supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technology, as well as the first and only organization capable of screening DELs within a living cell. Vipergen's patented portfolio of cutting-edge DEL technologies is made accessible by funded discovery collaborations with leading pharmaceutical and biotechnology firms, including top pharmaceutical companies in the United States, Europe, and Japan.

Read More